E

Enliven Therapeutics
D

ELVN

43.790
USD
-1.53
(-3.38%)
قبل الجلسة
حجم التداول
4
الربح لكل سهم
-2
العائد الربحي
-
P/E
-24
حجم السوق
2,618,659,779
المقالات
المزيد

العنوان: Enliven Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.